JP6660369B2 - 神経障害を治療する方法 - Google Patents

神経障害を治療する方法 Download PDF

Info

Publication number
JP6660369B2
JP6660369B2 JP2017501186A JP2017501186A JP6660369B2 JP 6660369 B2 JP6660369 B2 JP 6660369B2 JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017501186 A JP2017501186 A JP 2017501186A JP 6660369 B2 JP6660369 B2 JP 6660369B2
Authority
JP
Japan
Prior art keywords
rats
dose
composition
patient
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017501186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519807A (ja
JP2017519807A5 (OSRAM
Inventor
ジョン ジャハンガー アラム，
ジョン ジャハンガー アラム，
Original Assignee
イーアイピー ファーマ， エルエルシー
イーアイピー ファーマ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーアイピー ファーマ， エルエルシー, イーアイピー ファーマ， エルエルシー filed Critical イーアイピー ファーマ， エルエルシー
Publication of JP2017519807A publication Critical patent/JP2017519807A/ja
Publication of JP2017519807A5 publication Critical patent/JP2017519807A5/ja
Application granted granted Critical
Publication of JP6660369B2 publication Critical patent/JP6660369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017501186A 2014-07-09 2015-07-08 神経障害を治療する方法 Active JP6660369B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022586P 2014-07-09 2014-07-09
US62/022,586 2014-07-09
PCT/US2015/039539 WO2016007616A1 (en) 2014-07-09 2015-07-08 Methods for treating neurologic disorders

Publications (3)

Publication Number Publication Date
JP2017519807A JP2017519807A (ja) 2017-07-20
JP2017519807A5 JP2017519807A5 (OSRAM) 2018-08-16
JP6660369B2 true JP6660369B2 (ja) 2020-03-11

Family

ID=55064826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501186A Active JP6660369B2 (ja) 2014-07-09 2015-07-08 神経障害を治療する方法

Country Status (5)

Country Link
US (1) US9579322B2 (OSRAM)
EP (1) EP3166610B1 (OSRAM)
JP (1) JP6660369B2 (OSRAM)
CN (3) CN113018300B (OSRAM)
WO (1) WO2016007616A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018300B (zh) 2014-07-09 2025-11-25 爱普制药有限责任公司 用于治疗神经病症的方法
WO2017075013A1 (en) 2015-10-26 2017-05-04 Eip Pharma, Llc Methods and compositions for recovery from stroke
EP3445369A4 (en) 2016-04-21 2020-03-04 Eip Pharma, LLC COMPOSITIONS AND METHODS FOR TREATING DEMENTIA
WO2019056003A1 (en) 2017-09-18 2019-03-21 Eip Pharma, Llc CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745)
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019178153A1 (en) * 2018-03-12 2019-09-19 Eip Pharma, Llc Pharmaceutical formulations of neflamapimod
AU2019384074B2 (en) * 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
AU2020295410A1 (en) * 2019-06-18 2022-01-20 Indivior Uk Limited Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
AU2020296012A1 (en) 2019-06-18 2022-01-20 Indivior Uk Limited Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
CA3147271A1 (en) * 2019-07-12 2021-01-21 Eip Pharma, Inc. Compositions and methods for treating dementia with lewy bodies
WO2022099095A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Treatment of gait dysfunction in neurodegenerative disease
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
US20240363225A1 (en) * 2023-04-27 2024-10-31 Remepy Health Ltd Digital therapeutics for improved neuro-connectivity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
CN101103969A (zh) * 2002-12-24 2008-01-16 神经化学（国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
US20050203111A1 (en) 2004-03-12 2005-09-15 Vvii Newco 2003, Inc. Compositions and methods for preventing and treating skin and hair conditions
US20080044439A1 (en) 2004-03-11 2008-02-21 David Nathaniel E Compositions and Methods for Preventing and Treating Skin and Hair Conditions
EP1948599A1 (en) 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
JP5432710B2 (ja) 2006-06-23 2014-03-05 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ Ａβ及びシヌクレイン凝集の阻害剤
US8304413B2 (en) * 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
RU2013149800A (ru) * 2011-04-08 2015-05-20 Афраксис Холдингз, Инк. 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака
EP2707369B1 (en) * 2011-05-09 2016-07-27 Eip Pharma, LLC Compositions and methods for treating alzheimer's disease
CN113018300B (zh) 2014-07-09 2025-11-25 爱普制药有限责任公司 用于治疗神经病症的方法

Also Published As

Publication number Publication date
EP3166610A4 (en) 2017-11-29
EP3166610A1 (en) 2017-05-17
JP2017519807A (ja) 2017-07-20
CN106659723A (zh) 2017-05-10
CN113018300B (zh) 2025-11-25
WO2016007616A1 (en) 2016-01-14
US20160008364A1 (en) 2016-01-14
CN113018300A (zh) 2021-06-25
CN114010641A (zh) 2022-02-08
US9579322B2 (en) 2017-02-28
EP3166610B1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
JP6660369B2 (ja) 神経障害を治療する方法
CN103842362B (zh) 用于治疗阿尔茨海默氏病的组合物和方法
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
BR112013029609A2 (pt) ligante sigma,uso de ligante sigma, método para o tratamento e/ou profilaxia de dores associadas ao diabetes tipo 2 e combinação de pelo menos um ligante sigma
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
US9427439B1 (en) Methods and compositions for recovery from stroke
JP6959371B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
JP2019516699A (ja) 純粋な５−ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組合せ
JP6629464B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
JP6606298B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
KR20170106485A (ko) 요산 또는 통풍 질환의 예방 또는 치료
HK40068517A (en) Methods for treating neurologic disorders
JP2006513207A (ja) 行動障害の治療のためのイストラデフィリン（ｋｗ−６００２）の使用
HK1260485B (en) Methods and compositions for recovery from stroke
HK1260485A1 (en) Methods and compositions for recovery from stroke
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1230184B (en) Compositions and methods for treating alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200207

R150 Certificate of patent or registration of utility model

Ref document number: 6660369

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250